MicroPhage is focused on improving health worldwide through leadership in rapid, direct bacterial identification and antimicrobial susceptibility testing.

The Company develops and will market diagnostics for the clinical marketplace through the use of its bacteriophage enabling technology, including high performing, easy to use tests for the direct identification of Staphylococcus aureus (S. aureus) and rapid antibiotic testing of methicillin susceptible and resistant S. aureus (MSSA and MRSA).